A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

LESSONS LEARNED. The combination of the antiangiogenic agent ziv‐aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested. Studies such as these emphasize the importance of con...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Meehan, Robert, Kummar, Shivaani, Do, Khanh, O'Sullivan Coyne, Geraldine, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Doroshow, James H., Chen, Alice P.
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2018
Subjects:
Clinical Trial Results
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291327/
https://ncbi.nlm.nih.gov/pubmed/29853657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0203
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items